Extended Safety, Immunogenicity and Efficacy of a Blood-Stage Malaria Vaccine in Malian Children: 24-Month Follow-Up of a Randomized, Double-Blinded Phase 2 Trial

BACKGROUND: The FMP2.1/AS02(A) candidate malaria vaccine was tested in a Phase 2 study in Mali. Based on results from the first eight months of follow-up, the vaccine appeared well-tolerated and immunogenic. It had no significant efficacy based on the primary endpoint, clinical malaria, but marginal...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:
গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Laurens, Matthew B., Thera, Mahamadou A., Coulibaly, Drissa, Ouattara, Amed, Kone, Abdoulaye K., Guindo, Ando B., Traore, Karim, Traore, Idrissa, Kouriba, Bourema, Diallo, Dapa A., Diarra, Issa, Daou, Modibo, Dolo, Amagana, Tolo, Youssouf, Sissoko, Mahamadou S., Niangaly, Amadou, Sissoko, Mady, Takala-Harrison, Shannon, Lyke, Kirsten E., Wu, Yukun, Blackwelder, William C., Godeaux, Olivier, Vekemans, Johan, Dubois, Marie-Claude, Ballou, W. Ripley, Cohen, Joe, Dube, Tina, Soisson, Lorraine, Diggs, Carter L., House, Brent, Bennett, Jason W., Lanar, David E., Dutta, Sheetij, Heppner, D. Gray, Plowe, Christopher V., Doumbo, Ogobara K.
বিন্যাস: Artigo
ভাষা:Inglês
প্রকাশিত: Public Library of Science 2013
বিষয়গুলি:
Research Article
অনলাইন ব্যবহার করুন:https://ncbi.nlm.nih.gov/pmc/articles/PMC3832522/
https://ncbi.nlm.nih.gov/pubmed/24260195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0079323
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

অনুরূপ উপাদানগুলি